新型冠状病毒肺炎非重症患者临床恶化的预测因素:一项回顾性队列研究。
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
作者信息
Yitao Zhang, Mu Chen, Ling Zhou, Shiyao Cheng, Jiaojie Xue, Zhichong Chen, Huajing Peng, Maode Ou, Kanglin Cheng, Mao Ou Yang, Xiaoneng Mo, Weijie Zeng
机构信息
The Cardiovascular Department, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Pulmonology, Guangzhou Eighth People's Hospital, Guangzhou, China.
出版信息
Curr Med Res Opin. 2021 Mar;37(3):385-391. doi: 10.1080/03007995.2021.1876005. Epub 2021 Feb 4.
OBJECTIVE
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains pandemic with considerable morbidity and mortality around the world. The aim of this study was to identify the predictors for clinical deterioration in patients with COVID-19 who did not show clinical deterioration upon hospital admission.
METHODS
Two hundred fifty-seven patients with confirmed COVID-19 pneumonia admitted to Guangzhou Eighth People's Hospital between 23 January and 21 March 2020 were retrospectively enrolled. Demographic data, symptoms, laboratory values, comorbidities and treatments were all collected. The study endpoint was clinical deterioration within 20 days from hospital admission. Univariate and multivariable logistic regression methods were used to explore the risk factors associated with clinical deterioration.
RESULTS
A total of 49 (19%) patients showed clinical deterioration after admission. Compared with patients that did not experience clinical deterioration, clinically deteriorated patients had more dyspnea, cough and myalgia (65.3% versus 29.3%) symptoms and more had comorbidities (89.8% versus 36.1%). Clinical and laboratory characteristics at admission that were associated with clinical deterioration included senior age, diabetes, hypertension, myalgia, higher temperature, systolic blood pressure, C-reactive protein (CRP), procalcitonin, activated partial thromboplastin time, aspartate aminotransferase, alanine transaminase, direct bilirubin, plasma creatinine, lymphocytopenia, thrombocytopenia, decreased albumin and bicarbonate concentration. Medical history of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, calcium channel blockers and metformin were also risk factors.
CONCLUSION
The four best predictors for clinical deterioration were CRP, procalcitonin, age and albumin. A "best" multivariable prediction model, resulting from using a variable selection procedure, included senior age, presentation with myalgia, and higher level of CRP and serum creatinine (bias-corrected -statistic = 0.909). Sensitivity and specificity corresponding to a cut point of CRP ≥18.45 mg/L for predicting clinical deterioration were 85% and 74%, respectively.
目的
由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)仍在全球大流行,导致相当高的发病率和死亡率。本研究的目的是确定入院时未出现临床恶化的COVID-19患者临床恶化的预测因素。
方法
回顾性纳入2020年1月23日至3月21日期间收治于广州市第八人民医院的257例确诊COVID-19肺炎患者。收集人口统计学数据、症状、实验室检查值、合并症及治疗情况。研究终点为入院后20天内的临床恶化情况。采用单因素和多因素logistic回归方法探讨与临床恶化相关的危险因素。
结果
共有49例(19%)患者入院后出现临床恶化。与未发生临床恶化的患者相比,发生临床恶化的患者有更多的呼吸困难、咳嗽和肌痛(65.3%对29.3%)症状,且合并症更多(89.8%对36.1%)。入院时与临床恶化相关的临床和实验室特征包括高龄、糖尿病、高血压、肌痛、体温较高、收缩压、C反应蛋白(CRP)、降钙素原、活化部分凝血活酶时间、天冬氨酸转氨酶、丙氨酸转氨酶、直接胆红素、血肌酐、淋巴细胞减少、血小板减少、白蛋白降低和碳酸氢盐浓度降低。血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、钙通道阻滞剂和二甲双胍的用药史也是危险因素。
结论
临床恶化的四个最佳预测因素为CRP、降钙素原、年龄和白蛋白。通过变量选择程序得出的“最佳”多因素预测模型包括高龄、有肌痛表现以及较高水平的CRP和血清肌酐(偏差校正后的 -统计量 = 0.909)。预测临床恶化的CRP切点≥18.45mg/L时,敏感性和特异性分别为85%和74%。